GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
The integration and transition of the brands are expected to be completed by June 2022.
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Subscribe To Our Newsletter & Stay Updated
